Please assess the completion status of the following clinical trial:

Trial Title: Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clopidogrel-naïve stable angina pectoris (CCS I-III)~* Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter stenosis greater than 50% in two independent projections) feasible for ad hoc stent implantation~Exclusion Criteria:~* Acute coronary syndrome (STEMI, NSTEMI or unstable angina)~* Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks~* Contraindication to antiplatelet therapy~* Significant LM stenosis~* PCI due to instent restenosis~* Lesion located in bypass grafts~* Stroke in past one year~* Reduced life expectancy

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
- 2 (Type: EXPERIMENTAL): Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
- 3 (Type: ACTIVE_COMPARATOR): Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel

Based on this trial design, predict the completion outcome and termination type (if applicable).